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We have used the forward mutation to resistance to 6 azauracil to test the mutagenicity of
rivanol (6, 9 diamino 2-ethoxy acridine) on Escherichia coli. Rivanol has been used to induce
therapeutic abortions in midpregnancy and is considered safe and effective for this purpose.
The findings reported here that rivanol, like other acridines, is a mutagen, at least in pro-
caryotes, suggests that such use ofrivanol be reconsidered in light ofits possiblegenetic toxicity.
INTRODUCTION
Rivanol is a substituted diaminoacridine compound (6, 9 diamino 2-ethoxy
acridine, Fig. 1) used in Asia and Sweden as an abortifacient for midtrimester abor-
tion by extra-amniotic instillation [1,2,3]. Some reports suggest that rivanol is safer
than saline for such abortions because of the absence of potential salt toxicity and
because of the intrinsic antibacterial activity of rivanol and consequently fewer in-
fections.
The apparent safety of rivanol has been documented in several large series of pa-
tients reported by Manabe and Manabe [2] and Ingemanson [3]. However, these
reports considered only the short-term effects of this agent. Since rivanol is an
acridine, a class of compounds known to bind strongly to DNA and to produce
mutations [4,5,6], it is appropriate to consider the potential of rivanol to produce
genetic damage, cancer, or other late sequelae. In this report we present evidence
that in one bacterial mutagenicity test system, rivanol has significant mutagenicity.
In light ofthis finding, it would seem reasonable that the need for rivanol abortions
be especially carefully considered and that rivanol be evaluated in other systems to
study its genetic toxicology.
MATERIALS AND METHODS
Bacteria: Escherichia coli SYMW is a derivative of E. coli K12 which has the
genetic markers supF, supE, gal, and hsdR. The relevant phenotype for the present
study is that the strain is wild-type at the upp locus (uracil phosphoribosyl
transferase, called uraP by Miller [7]). Forward mutations from upp+ to upp- were
scored bytheability ofthe mutant but notthewild-type bacteria to grow on minimal
plates with glucose in the presence of30 ig/ml of6-azauracil [7]. E. coliSYMW was
grown on Luria broth (10 gm tryptone, 5 gm yeast extract, 0.5 gm NaCl per liter) at
370C.
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FIG. 1. Structure of 6.9 diamino-2-ethoxy acridine. This
compound is also known by the trivial names rivanol,
ethodin, and ethacridine.
Chemicals: Rivanol (ethodin) was purchased from Sigma and was used without
further purification. Acridine orange was purchased from Allied Chemical Company.
RESULTS
In order to test for the mutagenicity of rivanol and a related, known mutagen,
acridine orange, we grew E. coli cells for many generations in the presence of these
agents at various initial concentrations and then determined the frequencies of the
cells with the mutant phenotype among the viable cells in the population. Specifically,
we inoculated Luria broth cultures which had-rivanol or acridine orange present at
different concentrations and allowed growth to proceed at 37°C to stationary phase.
A uniform inoculum, about 10' cells per ml, was used in each experiment. After
12-14 hours growth at 37°C with aeration, two determinations were made: the con-
centration of viable cells was determined by plating dilutions of each culture on
Luria broth agar; the concentration of upp mutants in the population was determined
by plating dilutions of each culture on minimal glucose containing agar which also
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FIG. 2. Viable cell counts in cultures grown in the
presence of various initial concentrations of rivanol
or acridine orange. Four independent experiments
were carried out and the data averaged. The error
bars indicate thestandard error ofthe mean foreach
drug concentration.
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DRUG CONCENTRATION These determinations were carried out on the same
(pg /mI) cultures analyzed in Fig. 2.
contained 30Fg/ml of6-azauracil. The ratio ofthe latter to the former number gave
the frequencies of upp mutants in each population.
Figure 2 shows the concentration of viable cells as a function of increasing con-
centrations of rivanol or acridine orange. In all experiments the rivanol-treated
samples had fewer viable cells per ml than the untreated controls. Such toxicity by
acridine orange was not observed at the concentrations tested.
The frequency of mutants in the treated and control cultures is shown in Fig. 3.
Acridine orange at concentrations less than or equal to 100 /g/ml did not increase
the frequency of upp mutants. However, rivanol exhibited a dose-dependent in-
crease in mutant frequency up to eightfold at 100 Ag/ml.
DISCUSSION
Rivanol has a structure quite similar to other acridines which are known bacterial
mutagens [4,8]. In general, the acridines and proflavines have been found to be
rather weak carcinogens when tested in mammalian systems [9,10]. Rivanol,
however, binds two to five times more strongly to DNA than the commonly studied
compounds acridine orange and proflavine [5,6]. This fact may account for the
selective bacterial toxicity we observed when comparingrivanol and acridine orange.
Our failure to detect significant mutagenicity with acridine orange is not surpris-
ing since we used a concentration of drug insufficient to cause any inhibition of
growth. Mutagenicity depends on achieving a significant intracellular concentration
of the drug, a concentration that frequently results in killing of a certain fraction of
the organisms. Also the relative permeability of a given bacterial strain to a specific
agent has been related to its mutagenicity in the case ofproflavine [11]. The bacteria
grown in rivanol showed a dose-related increase in mutation frequency which was
significantly different from the untreated controls at 100 yg/ml (0.01 < p < 0.025).
The mutational test system employed in this study is relatively general; that is, it
should detect mutagens regardless of their mutational specificity or mechanism.
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This is because the system scores forward mutations or loss of a gene function. Any
type of mutation that results in a non-functional uracil phosphoribosyl transferase
enzyme confers 6-azauracil resistance onthecell. Thus, frame-shift mutations, point
mutations, and genomic rearrangements are all detected by this system. Although
this system does not have the specificity ofsome ofthe reverse mutation test systems
devised by Ames and his colleagues [8], it might be increased in sensitivity by addi-
tion of mutations which increase permeability to acridines and which block certain
DNA repair pathways [11].
The use ofrivanol forextra-amniotic instillation to induce midtrimenster abortion
is widespread in Asia [1] and has been employed in Sweden as well [3]. Its safety in
terms of immediate side effects seems to compare favorably with other agents. The
genetic toxicity of this agent remains to be evaluated, however. It may be that
rivanol is not absorbed into the maternal circulation, but it would be surprising if
some of the extra-amniotic rivanol solution could not find its way through the
decidua into the maternal blood and lymphatic drainages. Few physiologic studies
have been published to help settle this issue. Lewis et al. [12] measured the rivanol
concentration in plasma of women receiving this drug for therapeutic abortion.
They found peak levels of 0.02 jig/ml. Rising et al. [13] found that orally adminis-
tered rivanol is poorly absorbed by humans and that most of the administered drug
is excreted in the feces. Still, they found that about one percent of the ingested
rivanol was absorbed and partially metabolized. These low blood levels that seem to
occur after oral or extra-amniotic application may be below theconcentration which
can cause significant genetic damage or induce malignancies. On the other hand,
mammalian cells may be more permeable to these compounds than are bacterial
cells, so low concentrations may pose significant risks. It is clear that such con-
siderations need further investigation and that the group of patients treated with
rivanol ought to be followed for a sufficient period of time to evaluate the possible
long-term effects of this agent.
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